To the Editor: Since the publication of a report by Safer et al. (N Engl J Med 287:217, 1972), which called attention to a depression of growth in hyperactive children on stimulant drugs, the controversy regarding the use of amphetamines and methylphenidate for the treatment of behavior and learning disorders has heightened. Despite the proved value of Central-nervous-system stimulants as an adjunct to the remedial education of the hyperactive child with minimal brain dysfunction, this form of therapy is sometimes withheld, particularly in children of sparse build, because of possible growth suppression. Dietary and other unproved remedies have been proposed . . .